831 related articles for article (PubMed ID: 17697453)
1. Modeling the economic and health consequences of managing chronic osteoarthritis pain with opioids in Germany: comparison of extended-release oxycodone and OROS hydromorphone.
Ward A; Bozkaya D; Fleischmann J; Dubois D; Sabatowski R; Caro JJ
Curr Med Res Opin; 2007 Oct; 23(10):2333-45. PubMed ID: 17697453
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and tolerability of once-daily OROS hydromorphone and twice-daily extended-release oxycodone in patients with chronic, moderate to severe osteoarthritis pain: results of a 6-week, randomized, open-label, noninferiority analysis.
Hale M; Tudor IC; Khanna S; Thipphawong J
Clin Ther; 2007 May; 29(5):874-888. PubMed ID: 17697906
[TBL] [Abstract][Full Text] [Related]
3. Opioids and the management of chronic severe pain in the elderly: consensus statement of an International Expert Panel with focus on the six clinically most often used World Health Organization Step III opioids (buprenorphine, fentanyl, hydromorphone, methadone, morphine, oxycodone).
Pergolizzi J; Böger RH; Budd K; Dahan A; Erdine S; Hans G; Kress HG; Langford R; Likar R; Raffa RB; Sacerdote P
Pain Pract; 2008; 8(4):287-313. PubMed ID: 18503626
[TBL] [Abstract][Full Text] [Related]
4. A randomized study to demonstrate noninferiority of once-daily OROS(®) hydromorphone with twice-daily sustained-release oxycodone for moderate to severe chronic noncancer pain.
Binsfeld H; Szczepanski L; Waechter S; Richarz U; Sabatowski R
Pain Pract; 2010; 10(5):404-15. PubMed ID: 20384968
[TBL] [Abstract][Full Text] [Related]
5. Multicenter, open-label, prospective evaluation of the conversion from previous opioid analgesics to extended-release hydromorphone hydrochloride administered every 24 hours to patients with persistent moderate to severe pain.
Weinstein SM; Shi M; Buckley BJ; Kwarcinski MA
Clin Ther; 2006 Jan; 28(1):86-98. PubMed ID: 16490582
[TBL] [Abstract][Full Text] [Related]
6. OROS® hydromorphone in chronic pain management: when drug delivery technology matches clinical needs.
Coluzzi F; Mattia C
Minerva Anestesiol; 2010 Dec; 76(12):1072-84. PubMed ID: 21102402
[TBL] [Abstract][Full Text] [Related]
7. [Pharmacotherapy of chronic, non-tumour related pain. Efficacy, tolerability and patient benefit of an oral osmotic system with hydromorphone].
Sabatowski R; Giesecke T
MMW Fortschr Med; 2007 Sep; 149 Suppl 3():119-24. PubMed ID: 17955789
[TBL] [Abstract][Full Text] [Related]
8. Sustained safety and efficacy of once-daily hydromorphone extended-release (OROS® hydromorphone ER) compared with twice-daily oxycodone controlled-release over 52 weeks in patients with moderate to severe chronic noncancer pain.
Richarz U; Waechter S; Sabatowski R; Szczepanski L; Binsfeld H
Pain Pract; 2013 Jan; 13(1):30-40. PubMed ID: 22510252
[TBL] [Abstract][Full Text] [Related]
9. Cost-effectiveness of strong opioids focussing on the long-term effects of opioid-related fractures: a model approach.
Hass B; Lungershausen J; Hertel N; Poulsen Nautrup B; Kotowa W; Liedgens H
Eur J Health Econ; 2009 Jul; 10(3):309-21. PubMed ID: 19101743
[TBL] [Abstract][Full Text] [Related]
10. Economic evaluation of OROS hydromorphone for chronic pain: a Pan-European perspective.
Hauber AB; Fleischmann J; Lothgren M; Wilson M; Lam A; Dubois D; Sabatowski R
J Opioid Manag; 2011; 7(4):287-96. PubMed ID: 21957828
[TBL] [Abstract][Full Text] [Related]
11. Clinical effectiveness and safety of OROS® hydromorphone in break-through cancer pain treatment: a multicenter, prospective, open-label study in Korean patients.
Lee KH; Kim MK; Hyun MS; Kim JY; Park KU; Song HS; Lee SA; Lee WS; Bae SH; Ryoo HM; Cho YY
J Opioid Manag; 2012; 8(4):243-52. PubMed ID: 22941852
[TBL] [Abstract][Full Text] [Related]
12. Economic evaluation of controlled-release oxycodone vs oxycodone-acetaminophen for osteoarthritis pain of the hip or knee.
Marshall DA; Strauss ME; Pericak D; Buitendyk M; Codding C; Torrance GW
Am J Manag Care; 2006 Apr; 12(4):205-14. PubMed ID: 16610922
[TBL] [Abstract][Full Text] [Related]
13. Comparative clinical efficacy and safety of a novel controlled-release oxycodone formulation and controlled-release hydromorphone in the treatment of cancer pain.
Hagen NA; Babul N
Cancer; 1997 Apr; 79(7):1428-37. PubMed ID: 9083166
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety profile of a single dose of hydromorphone compared with morphine in older adults with acute, severe pain: a prospective, randomized, double-blind clinical trial.
Chang AK; Bijur PE; Baccelieri A; Gallagher EJ
Am J Geriatr Pharmacother; 2009 Feb; 7(1):1-10. PubMed ID: 19281935
[TBL] [Abstract][Full Text] [Related]
15. Randomized trial comparing polymer-coated extended-release morphine sulfate to controlled-release oxycodone HCl in moderate to severe nonmalignant pain.
Nicholson B; Ross E; Sasaki J; Weil A
Curr Med Res Opin; 2006 Aug; 22(8):1503-14. PubMed ID: 16870075
[TBL] [Abstract][Full Text] [Related]
16. Economic evaluation of Durogesic in moderate to severe, nonmalignant, chronic pain in Germany.
Greiner W; Lehmann K; Earnshaw S; Bug C; Sabatowski R
Eur J Health Econ; 2006 Dec; 7(4):290-6. PubMed ID: 16983521
[TBL] [Abstract][Full Text] [Related]
17. Once-daily OROS hydromorphone ER compared with placebo in opioid-tolerant patients with chronic low back pain.
Hale M; Khan A; Kutch M; Li S
Curr Med Res Opin; 2010 Jun; 26(6):1505-18. PubMed ID: 20429852
[TBL] [Abstract][Full Text] [Related]
18. Dose conversion and titration with a novel, once-daily, OROS osmotic technology, extended-release hydromorphone formulation in the treatment of chronic malignant or nonmalignant pain.
Palangio M; Northfelt DW; Portenoy RK; Brookoff D; Doyle RT; Dornseif BE; Damask MC
J Pain Symptom Manage; 2002 May; 23(5):355-68. PubMed ID: 12007754
[TBL] [Abstract][Full Text] [Related]
19. Budget impact analysis of tapentadol extended release for the treatment of moderate to severe chronic noncancer pain.
Merchant S; Noe LL; Howe A; Duff S; Gricar J; Ogden K; Mody SH
Clin Ther; 2013 May; 35(5):659-72. PubMed ID: 23587608
[TBL] [Abstract][Full Text] [Related]
20. Open-label study to evaluate the efficacy and safety of extended-release hydromorphone in patients with chronic neuropathic pain.
Nalamachu S; Ruck D; Nalamasu R; Fasbinder S; Bansal R
J Opioid Manag; 2013; 9(1):43-9. PubMed ID: 23709303
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]